No 3 (2016)

The prevalence of metabolic syndrome (MS) and its individual components in patients with gout was studied. Total risk of cardiovascular disease (CVD) in this group of patients was evaluated. The study involved 86 patients, the study group comprised 56 patients with primary chronic gout and MS, the comparison group consisted of 30 volunteers with MS without gout or any other inflammatory process. All patients underwent assessment of total CVD risk according to the PROCAM and SCORE scales. At least 1 additional symptom of MS was diagnosed in aft examined patients. In 13 patients (23,21%) of the main group and 1 (3,33%) patient of the comparison group aft 5 additional signs were identified. In patients of the main group we often identified more than 3 additional signs of MS. Arterial hypertension was detected in patients with MS regardless of the presence of gout. Total risk of CVD in patients of the main group was refiabfy higher in comparison with the group with isolated MS (p<0,01 for SCORE and p<0,05 for PROCAM).

In 102 patients (79 men, 23 women, ages of 21,9±4,4 years) with connective tissue dysplasia (CTD) were revealed significant changes in plasma levels of adhesion molecules: increased E-selectin, intercellular adhesion molecule 1 type (ICAM-1), vascular adhesion molecule 1 type (VCAM-1) and decreased platelet endothelial adhesion molecule 1 type. It was determined the correlation of elevated concentrations of E-selectin, ICAM- 1 and VCAM-1 with the clinical manifestations of CTD (classified dysplastic syndrome/phenotype, moderate regurgitation on prolapse mitral valve, cardiac arrhythmias and conduction, «white coat hypertension», arterial hypotension, chronic tonsillitis). The results allow pathogenetically substantiated the formation of subject groups to dispensary supervision.

The red blood parameters, electric and viscoelastic characteristics of of red blood cells, their relationship with biochemistry indices in patients with various stages of colorectal cancer were investigated. The functional characteristics of erythrocytes were studied by the method of dielectrophoresis. The amplitude of deformation of red blood cells, summarized viscosity and rigidity were significant to distinguish the different stages of the disease, while the spent therapy also affects the change of polarizability, capacity of membranes and the value of dipole moment. Correlations viscoelastic and electrical parameters of red blood cells with biochemical parameters were revealed.

The article presents modern views on the mechanisms of development and approaches to antihypertensive therapy, the place of moxonidine in patients with abdominal obesity, metabolic syndrome and diabetes mellitus type 2. Moxonidine (Physiotens), selectively affecting the imidazoline type 1 receptors of the sympathetic vasomotor centers of ventrolateral part of the rostral department of oblong brain and renal tubules, is an effective antihypertensive drug. In addition, moxonidine effect on imidazoline receptors located in the pancreas and adipocytes by exerting a positive influence on metabolic processes. It increases the sensitivity of tissues to insulin and improves carbohydrate and lipid metabolism. Although moxonidine is not related to the first-line of antihypertensive drugs, there are a large number of patients for whom moxonidine is the drug of choice, in particular, these are patients with prediabetes and diabetes mellitus type 2.

The review deals with the analysis of randomized controlled clinical trials of the efficiency and safety of gLimepiride, both as part of monotherapy and in combination with other antidiabetic agents. For the analysis were selected only those studies which aim was to evaluate the effectiveness of the correction of carbohydrate metabolism and decrease of glycemia. It is concluded that the addition of glimepiride to hypoglycemic therapy is accompanied by marked clinical effect and good safety profile, which shows lower incidence of hypoglycemia and no or negligible increase of body weight.

The article describes the modern view of the treatment of patients with comorbid disorders: arterial hypertension (AH) and chronic bronchopulmonary diseases. The relationship of hypertension and chronic obstructive pulmonary disease (COPD) is ambiguous interpretation as to their pathogenic interaction. There are two points of view on the combination of hypertension and COPD: 1 ) the coexistence of the two diseases, developing under the influence of the common risk factors and pathogenesis of unrelated; 2). COPD is the cause of hypertension, which gives reason to treat hypertension in these patients as symptomatic (pulmogenic AH). Hypertension and COPD bring together common risk factors that play an important role in the course and progression of each of these two diseases. These factors include: smoking, overweight, physical inactivity, obstructive sleep apnea syndrome and others. According to most researchers, the main mechanism for the development of systemic hypertension in patients with COPD is hypoxia. The article deals with modern approaches to the treatment of patients with hypertension and COPD. It is likely that we will soon get a new interesting information about the clinical use and safety of several drugs used to treat hypertension, on the one hand, and COPD, on the other, that will open up new possibilities in the treatment of this category of patients.

Authors present a description of a patient with cerebral [migraine-Like and meningeal) variant of familial Mediterranean fever (periodic disease) complicated by amyloidosis. After many years of monosymptomatic currents disease manifested with abdominal crisis and the formation of other symptoms in the form of lesions of the skin, eyes, muscle pain and symptoms from the upper respiratory tract.